BetaPublic beta

Spending
Lobbying
Coming soon: Congress, Stocks

Spending
- Overview
- Agencies
- Programs
- Recipients
- Awards
Lobbying
Congress
Stocks

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Lobbying
Coming soon: Congress, Stocks

Overview Firms Clients Revolving Door Stands Out

KRS GLOBAL BIOTECHNOLOGY — Lobbying — Receipts Report

LD-2 disclosure · 4th Quarter - Report

KRS GLOBAL BIOTECHNOLOGY

via PARRY, ROMANI, DECONCINI & SYMMS

4th Quarter (Oct 1 - Dec 31) · 2018Posted Jan 18, 2019Filing document ↗LDA record ↗

Income$15Kfee reported

Client

Name: KRS GLOBAL BIOTECHNOLOGY
Description: Compounding Pharmacy
Location: Florida · United States of America

Registrant

Firm: PARRY, ROMANI, DECONCINI & SYMMS
Description: Consulting
Location: Washington, District of Columbia, United States of America

Lobbying activities

1 issue

Pharmacy
Monitoring FDA Implementation of legislation affecting Compounding Pharmacies
LobbyistsSTEVE SYMMS · ROMANO ROMANI · JAMES ROCK
TargetedSENATE · HOUSE OF REPRESENTATIVES

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.